Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT is a phase 2, interventional study registered as NCT06222489 by The Netherlands Cancer Institute, with a registry enrolment figure of 16 participants, started 2025-03-03 and due to reach its primary completion in 2027-05-01. Interventions recorded: 89Zr-Patritumab deruxtecan. Conditions listed: Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer; EGFR Gene Mutation. Primary outcome: The optimal imaging dose patritumab deruxtecan to co-inject with 89Zr-Patritumab deruxtecan (HER3-DXd), defined by adequate visualisation of the circulation five days after tracer injection.. Lung eligibility wording from the registry: "Have a histologically or cytologically confirmed diagnosis of (locally) advanced stage EGFR mutation positive NSCLC, not amenable for curative intent treatment". Sites: Netherlands. No results are recorded here; the registry entry is the source.